专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08486983B2 Self-emulsifying formulations of CETP inhibitors 有权
标题翻译： CETP抑制剂的自乳化制剂
公开(公告)号：US08486983B2
公开(公告)日：2013-07-16
申请号：US12085745
申请日：2006-12-05
申请人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. McKelvey
发明人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. McKelvey
IPC分类号： A61K31/421
CPC分类号： A61K9/08 , A61K9/4858 , A61K31/421 , A61K47/10 , A61K47/26 , A61K47/44
摘要： A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
摘要翻译：用于口服给予式（I）的CETP抑制剂的液体制剂与常规固体制剂相比具有改善的生物利用度。该制剂包含CETP抑制剂或其药学上可接受的盐; 一油和一种或多种亲水亲油平衡（HLB）> 10的非离子表面活性剂。

2. 发明申请

US20090186926A1 Self-Emulsifying Formulations of CETP Inhibitors 有权
标题翻译： CETP抑制剂的自乳化制剂
公开(公告)号：US20090186926A1
公开(公告)日：2009-07-23
申请号：US12085745
申请日：2006-12-05
申请人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. Mckelvey
发明人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. Mckelvey
IPC分类号： A61K31/421
CPC分类号： A61K9/08 , A61K9/4858 , A61K31/421 , A61K47/10 , A61K47/26 , A61K47/44
摘要： A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
摘要翻译：用于口服给予式（I）的CETP抑制剂的液体制剂与常规固体制剂相比具有改善的生物利用度。该制剂包含CETP抑制剂或其药学上可接受的盐; 一油和一种或多种亲水亲油平衡（HLB）> 10的非离子表面活性剂。

3. 发明申请

US20090123538A1 Angiotensin II Receptor Antagonists 审中-公开
标题翻译：血管紧张素II受体拮抗剂
公开(公告)号：US20090123538A1
公开(公告)日：2009-05-14
申请号：US11886553
申请日：2006-04-14
申请人： Laman L. Alani , David C. Dubost , Bruce S. Foster , Soumojeet Ghosh , Hossain Jahansouz , Nazaneen Pourkavoos , Bhagwant Rege , Aditya Tatavarti
发明人： Laman L. Alani , David C. Dubost , Bruce S. Foster , Soumojeet Ghosh , Hossain Jahansouz , Nazaneen Pourkavoos , Bhagwant Rege , Aditya Tatavarti
IPC分类号： A61K9/20 , C07D257/04 , A61K31/41 , A61P9/12 , A61K9/16
CPC分类号： C07D403/10
摘要： The compounds of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, which has the structure (I). Specifically, the compounds of the invention are selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid of Claim 3 selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form I, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form II, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form III, and 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form IV, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form V, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VI, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VII, and 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VIII.
摘要翻译：本发明的化合物是2-丁基-4-氯-1 - （（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-1-基的化合物的多晶型形式，其具有结构（I）。具体地说，本发明化合物选自2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑 -5-羧酸，其选自2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑 -5-甲酸盐酸盐形式I，2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸盐酸盐形式II，2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸盐酸盐形式III和 2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸一水合物形式IV，2-丁基-4 - 氯 - 1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸一水合物形式V，2-丁基-4-氯-1- 甲基] - 咪唑-5-羧酸一水合物形式VI，2-丁基-4-氯-1 - [（2' - （1H-四唑-5-基）联苯-4-基）（1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5- c 羧酸一水合物形式VII和2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸一水合物形式八，

4. 发明申请

US20120202858A1 Solid Pharmaceutical Dosage Form 有权
标题翻译：固体药物剂型
公开(公告)号：US20120202858A1
公开(公告)日：2012-08-09
申请号：US13449958
申请日：2012-04-18
申请人： Jöerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jörg Breitenbach , Laman L. Alani , Soumojeet Ghosh
发明人： Jöerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jörg Breitenbach , Laman L. Alani , Soumojeet Ghosh
IPC分类号： A61K31/427 , A61P31/18
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

5. 发明申请

US20110008430A1 Solid Pharmaceutical Dosage Form 有权
公开(公告)号：US20110008430A1
公开(公告)日：2011-01-13
申请号：US12880766
申请日：2010-09-13
申请人： Jorg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
发明人： Jorg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
IPC分类号： A61K9/28 , A61K31/513 , A61P31/18
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

6. 发明申请

US20120022089A1 Solid Pharmaceutical Dosage Form 有权
公开(公告)号：US20120022089A1
公开(公告)日：2012-01-26
申请号：US13240119
申请日：2011-09-22
申请人： Jöerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jörg Breitenbach , Laman L. Alani , Soumojeet Ghosh
发明人： Jöerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jörg Breitenbach , Laman L. Alani , Soumojeet Ghosh
IPC分类号： A61K31/513
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

7. 发明申请

US20080299203A1 Solid Pharmaceutical Dosage Formulation 审中-公开
标题翻译：固体药物配方
公开(公告)号：US20080299203A1
公开(公告)日：2008-12-04
申请号：US12190252
申请日：2008-08-12
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
IPC分类号： A61K9/00 , A61K31/513 , A61K31/427
CPC分类号： A61K9/1694 , A61K9/1617 , A61K9/1635 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/204 , A61K9/2077 , A61K9/2095 , A61K9/2866 , A61K31/00 , A61K31/426 , A61K31/427 , A61K31/513 , A61K47/32 , A61P31/18 , A61K2300/00
摘要： The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
摘要翻译：本发明提供药物剂型，更特别地，包含HIV蛋白酶抑制剂的药物剂型。

8. 发明授权

US08377952B2 Solid pharmaceutical dosage formulation 有权
标题翻译：固体药物剂型
公开(公告)号：US08377952B2
公开(公告)日：2013-02-19
申请号：US11064467
申请日：2005-02-23
申请人： Jöerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jörg Breitenbach , Laman L. Alani , Soumojeet Ghosh
发明人： Jöerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jörg Breitenbach , Laman L. Alani , Soumojeet Ghosh
IPC分类号： A61K31/513 , A61K31/427
CPC分类号： A61K9/1694 , A61K9/1617 , A61K9/1635 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/204 , A61K9/2077 , A61K9/2095 , A61K9/2866 , A61K31/00 , A61K31/426 , A61K31/427 , A61K31/513 , A61K47/32 , A61K2300/00
摘要： The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
摘要翻译：本发明提供药物剂型制剂，更具体地，涉及包含HIV蛋白酶抑制剂的药物剂型。

9. 发明申请

US20090136570A1 Taste-Masked Tablets and Granules 审中-公开
标题翻译：味道掩蔽的片剂和颗粒
公开(公告)号：US20090136570A1
公开(公告)日：2009-05-28
申请号：US12087827
申请日：2007-01-16
申请人： Bhagwant Rege , Kimberly Kaighn , Soumojeet Ghosh , Laman Alani
发明人： Bhagwant Rege , Kimberly Kaighn , Soumojeet Ghosh , Laman Alani
IPC分类号： A61K9/20 , A61K31/513 , A61K31/519 , A61P31/18 , A61K31/506
CPC分类号： A61K9/2054 , A61K9/2018 , A61K9/2027 , A61K9/2095 , A61K31/70
摘要： Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a pharmaceutically acceptable salt thereof, (b) a taste-masking polymer, (c) a superdisintegrant, and optionally other excipients. The carboxamide compound is an HIV integrase inhibitor, and the tablets and granules are suitable for use in the inhibition of HIV integrase, the treatment or prophylaxis of HIV infection, and the treatment or prophylaxis or delay in the onset of AIDS.
摘要翻译：口服给药的掩味片和颗粒剂含有（a）羟基嘧啶酮羧酰胺，羟基四氢吡啶并嘧啶酮羧酰胺或相关的羧酰胺化合物或其药学上可接受的盐，（b）掩味聚合物，（c）超级崩解剂，和任选的其它赋形剂。甲酰胺化合物是HIV整合酶抑制剂，片剂和颗粒剂适用于抑制HIV整合酶，治疗或预防HIV感染，以及治疗或预防或延迟艾滋病的发作。

10. 发明授权

US08414921B2 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 有权
标题翻译：二肽基肽酶-4抑制剂与二甲双胍的组合药物组合物
公开(公告)号：US08414921B2
公开(公告)日：2013-04-09
申请号：US12085722
申请日：2006-12-12
申请人： Ashkan Kamali , Laman Alani , Kyle A. Fliszar , Soumojeet Ghosh , Monica Tijerina
发明人： Ashkan Kamali , Laman Alani , Kyle A. Fliszar , Soumojeet Ghosh , Monica Tijerina
IPC分类号： A61K9/20
CPC分类号： A61K9/2077 , A61K9/1635 , A61K9/2813 , A61K9/284 , A61K31/155 , A61K31/4985 , A61K38/04 , A61K45/06 , A61K2300/00
摘要： Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
摘要翻译：公开了包含二肽基肽酶-4抑制剂和二甲双胍的固定剂量组合的药物组合物，制备这种药物组合物的方法，以及用这种药物组合物治疗2型糖尿病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式